Cancer drug combination may increase risk of deathFebruary 17th 2011
Cancer patients treated with the angiogenesis inhibitor bevacizumab (Avastin) may be at an increased risk of treatment-related death when the drug is used in combination with other therapies, say researchers from Stony Brook University School of Medicine, Stony Brook, NY.
FDA issues complete response letter for 5-ARI PCa risk reduction indicationFebruary 10th 2011
GlaxoSmithKline has received a complete response letter from the FDA for the supplemental new drug application for dutasteride (Avodart) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum PSA level.
Advanced prostate cancer combination treatment fails to improve survivalFebruary 1st 2011
Results of a phase III trial failed to confirm data from a phase II study suggesting that the addition of high-dose oral calcitriol (DN-101) to docetaxel (Taxotere) confers a survival advantage and reduces toxicity versus treatment with docetaxel alone in men with progressive castration-resistant prostate cancer (CRPC).
Testosterone therapy safe in men with low-risk prostate cancer, study saysJanuary 1st 2011
Labeling on testosterone products sold in the United States indicates that testosterone supplementation is contraindicated in men with a history of prostate cancer and in those thought to be at risk for the disease. A recent study brings the validity of that warning into question.
Testosterone replacement therapy found safe in study of high-risk post-radical prostatectomy patientsJanuary 1st 2011
Results of a retrospective study including a series of post-radical prostatectomy patients with pathology-proven high-risk characteristics provide further insight into the use of testosterone replacement therapy in men with a history of prostate cancer.
FDA to drug companies: Include risk warnings for GnRH agonistsNovember 4th 2010
The FDA has asked drug manufacturers to add new warnings to labeling of gonadotropin-releasing hormone agonists to alert patients and health care professionals to the potential risk of heart disease and diabetes in men treated with these medications for prostate cancer.
Investigational agent improves overall survival in men with metastatic PCaOctober 28th 2010
Patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared with those treated with prednisone/prednisolone plus placebo, according to results from an interim analysis of a randomized, placebo-controlled phase III study.
Published data: New therapy improves survival in advanced PCaOctober 14th 2010
Cabazitaxel (Jevtana) injection, in combination with prednisone, reduced the risk of death by 30% in men with metastatic castration-resistant prostate cancer whose disease progressed following treatment with docetaxel (Taxotere)-based chemotherapy, according to a recent study.
Physicians may not yet accept prostate Ca chemopreventive agentSeptember 23rd 2010
Although finasteride (Proscar) was shown to be effective in reducing the incidence of prostate cancer in the Prostate Cancer Prevention Trial (PCPT), physicians apparently have not embraced the use of the agent for this indication, according to a recent study.
ASCO urges CMS to withdraw coverage analysis for PCa immunotherapySeptember 9th 2010
The American Society of Clinical Oncology has submitted comprehensive comments to the Centers for Medicare & Medicaid Services expressing concern about its decision to open a national coverage analysis (NCA) for sipuleucel-T (Provenge).
Efficacy of new advanced prostate cancer treatment affirmedSeptember 1st 2010
In men with metastatic castration- resistant prostate cancer who progressed after docetaxel (Taxotere)-based therapy, treatment with cabazitaxel (Jevtana) was associated with significantly better overall survival compared with mitoxantrone (Novantrone).
New agent treats symptoms of urinary tract conditionsAugust 26th 2010
Mission Pharmacal Co. has announced the introduction of methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, hyoscyamine sulfate (Uribel) capsules for oral administration to help relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome, and pre- and post-diagnostic urinary tract procedures.
Autologous immunotherapy prolongs survival in men with prostate cancerAugust 12th 2010
Sipuleucel-T (Provenge) appears to show a statistically significant improvement in overall survival in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, according to results of a recently published study.
Prostate cancer survival not improved with anti-angiogenic agentAugust 1st 2010
Preliminary results from a phase III trial do not support the research hypothesis that the addition of bevacizumab (Avastin) to a regimen combining docetaxel (Taxotere) and prednisone improves survival in patients with metastatic castration-resistant prostate cancer.
Investigational premature ejaculation therapy shows promiseJune 24th 2010
A topical metered dose spray known as PSD502, under development for the treatment of primary premature ejaculation, appears to offer improvement in time to ejaculation, according to data presented at the AUA annual meeting in San Francisco.